– Everolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients(1)
– Seizures are the most common TSC-related neurological condition, yet about 60% of patients don’t attain seizure control with available anti-epileptic therapies(2)
– Results presented at AAN will be discussed with health authorities for potential worldwide regulatory filings